Description

Simple

Clinical

Overview

Ramosetron is a _serotonin 5-HT3 receptor antagonist_ commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions. It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron. Currently, ramosetron is only approved for use Japan and in certain Southeast Asian countries.

Pharmacology

Indication

For the treatment of nausea and vomiting and diarrhea-predominant irritable bowel syndrome in males.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Ramosetron
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The metabolism of Ramosetron can be decreased when combined with (R)-warfarin.
(S)-Warfarin
The risk or severity of adverse effects can be increased when Ramosetron is combined with (S)-Warfarin.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Ramosetron is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Ramosetron.
4-hydroxycoumarin
The risk or severity of adverse effects can be increased when Ramosetron is combined with 4-hydroxycoumarin.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Ramosetron.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Ramosetron is combined with 5-methoxy-N,N-dimethyltryptamine.
6-O-benzylguanine
The metabolism of 6-O-benzylguanine can be decreased when combined with Ramosetron.
7-Nitroindazole
The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Ramosetron.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Ramosetron.
8-azaguanine
The metabolism of Ramosetron can be decreased when combined with 8-azaguanine.
8-chlorotheophylline
The metabolism of 8-chlorotheophylline can be decreased when combined with Ramosetron.
9-Deazaguanine
The metabolism of Ramosetron can be decreased when combined with 9-Deazaguanine.
9-Methylguanine
The metabolism of Ramosetron can be decreased when combined with 9-Methylguanine.
Abatacept
The metabolism of Ramosetron can be increased when combined with Abatacept.
Abiraterone
The serum concentration of Ramosetron can be increased when it is combined with Abiraterone.
Acefylline
The metabolism of Acefylline can be decreased when combined with Ramosetron.
Acenocoumarol
The metabolism of Ramosetron can be decreased when combined with Acenocoumarol.
Acepromazine
The risk or severity of adverse effects can be increased when Acepromazine is combined with Ramosetron.
Aceprometazine
The risk or severity of adverse effects can be increased when Aceprometazine is combined with Ramosetron.
2 References
  1. 1 . Fujii Y, Saitoh Y, Tanaka H, Toyooka H: Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery. Anesth Analg. 2000 Feb;90(2):472-5.PubMed: 10648342
  2. 2 . Lee SH, Cho SY, Yoo KY, Jeong S: Population pharmacokinetics of ramosetron. J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):73-83. doi: 10.1007/s10928-015-9455-8. Epub 2015 Nov 11.PubMed: 26558626